top of page
Our Focus

Our Approach: Publications

Ocelot Bio Publication 2023JUL07.png
Publication Link
Partial vasopressin 1a receptor agonism reduces portal hypertension and hyperaldosteronism and induces a powerful diuretic and natriuretic effect in rats with cirrhosis and ascites

September 2023
Biomedicine and Pharmacotherapy
Guillermo Fernández-Varo, Wladimiro Jiménez, Edward Cable, Pere Ginès, Geoff Harris, Stan Bukofzer
Ocelot OCE205 Clinical Drug Investigation.png
Publication Link
OCE-205, A Novel, Selective Vasopressin Receptor Mixed Agonist-Antagonist: Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics from a Phase 1 Study in Healthy Volunteers

August 2023
Clinical Drug Investigation
Yu Bagger, William R. Ravis, Geoff Harris, Stan Bukofzer
OCE-205 in rats and non-human primates.png
Publication Link
OCE-205 in rats and non-human primates: Pharmacokinetic and pharmacodynamic analysis

August 2023
Current Research in Pharmacology and Drug Discovery
Stan Bukofzer, Geoff Harris, Edward E. Cable
Selective Partial Agonism of Vasopressin 1a Receptors In Vitro by OCE-205.png
Publication Link
Selective Partial Agonism of Vasopressin 1a Receptors In Vitro by OCE-205

July 2023
Journal of Pharmacology and Pharmacotherapeutics
Glenn Croston, Edward E. Cable, Jeannine Toy, Hiroe Tariga, Regent Laporte, Geoff Harris, Stan Bukofzer
OCE-205 a Selective V1a Partial Agonist Reduces Portal Pressure in Rat Models of Portal Hy
Publication Link
OCE-205, a Selective V1a Partial Agonist, Reduces Portal Pressure in Rat Models of Portal Hypertension

July 2023
Journal of Experimental Pharmacology
Stan Bukofzer, Geoffrey Harris, Susan Song, Edward Cable
OCE-205, a Novel, Selective Vasopressin (V1a) Receptor Mixed Agonist-Antagonist: Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics from a Phase 1 Study

November 2022
Allan Blemings, Yu Bagger, William R. Ravis, Geoff Harris

(233KB PDF)

AASLD Poster PresentationOcelot Bio
00:00 / 04:45
Articles linked below are subject to restrictions from the respective publications and are not to be used for commercial purposes.
bottom of page